_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
This is the fourth facility from the company to receive this registration
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
The country’s top heart transplant surgeon Dr. K.R Balakrishnan to be leading the programme for Jaslok
Subscribe To Our Newsletter & Stay Updated
